Trilaciclib
Trilaciclib
Trilaciclib (pronounced tri-la-ci-clib) is a small molecule inhibitor of Cyclin-dependent kinases (CDK) 4 and 6. It is developed by G1 Therapeutics and is used in the treatment of various types of cancer.
Etymology
The name "Trilaciclib" is derived from the combination of the words "tri" (meaning three, referring to the three cyclin-dependent kinases it inhibits), "laci" (an abbreviation of "lactose", a sugar molecule that is part of the drug's structure), and "clib" (an abbreviation of "cyclin-dependent kinase inhibitor").
Usage
Trilaciclib is used in the treatment of small cell lung cancer (SCLC), breast cancer, and colorectal cancer. It is administered intravenously before chemotherapy to protect the immune system from damage caused by chemotherapy drugs.
Mechanism of Action
Trilaciclib works by inhibiting the activity of cyclin-dependent kinases 4 and 6. These kinases are proteins that control cell division. By inhibiting these kinases, Trilaciclib prevents cancer cells from dividing and growing.
Related Terms
- Cyclin-dependent kinases: A family of proteins that regulate the cell cycle by binding to cyclins.
- Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.
- Small cell lung cancer: A type of lung cancer that is characterized by small cells that grow and spread quickly.
- Breast cancer: A type of cancer that forms in the cells of the breasts.
- Colorectal cancer: A type of cancer that starts in the colon or rectum.
External links
- Medical encyclopedia article on Trilaciclib
- Wikipedia's article - Trilaciclib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski